Articles On Medadvisor (ASX:MDR)

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

MedAdvisor will pay £1 million (A$1.9 million) to UK pharmacy market app provider Charac Charac will see MedAdvisor pick up a 7.4 per cent shareholding MedAdvisor’s Rick Ratliff will become an NED on Charac’s board MedAdvisor wi...

So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Amplia reports positive data from pancreatic cancer trial Emyria was given endorsement by ethical committee for its TGA application MedAdvisor’s Q1 sales were up 27pc   Amplia reports promising data from pancreatic cancer trial Amplia The...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The ASX 200 benchmark falls 0.6% as we brace for news from The Fed Sector losses led by Resources, while Consumers make gains Small caps led by Alderan, and BNPL Sezzle returns   Local markets made it a hat trick of losses, with the re...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX is set to rise for a third consecutive day Tech stocks in the US rallied overnight after a soft jobs market report Dividends rose in Q2 in Australia and around the world   The ASX is set to open higher for a third consecutive day afte...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Salter Broth...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Despite the billions of dollars spent on developing new drugs, many of them are ineffective for a large number of patients. Is that a Big Pharma conspiracy to be revealed on the ABC’s Four Corners next Monday night? Er – no, actually. The...

Medadvisor [ASX:MDR], Australian developer of healthcare software for patients, announced its return back into profit in its half-year 2023 results announcement — declaring profits had surged 161%. Investors were tipping the MDR share price...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p...

December winner Meteoric Resources sees a non-executive director buy 6 million shares Northern Star Resources and Chalice Mining directors sell in December for tax obligations Johns Lyng Group COO Lindsay Barber sells 4 million shares, ~3...

On Wednesday, the S&P/ASX 200 Index (ASX: XJO) was back on form and charged notably higher. The benchmark index rose 1.3 % to 7,115.1 points. Will the market be able to build on this on Thursday? Here are five things to watch: ASX 20...

ASX 200 gold shares soared on Wednesday, but could a ‘pivot point’ for the gold price be on the way? Gold producers on the ASX 200 include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM), and Northern Star Resources Lt...

The S&P/ASX 200 Index (ASX: XJO) bounced back from yesterday’s chaos today. The index closed 1.3% higher at 7,115.1 points. Leading today’s gains on the Aussie bourse was the S&P/ASX 200 Utilities Index (ASX: XUJ). It rose 3.8%...

The S&P/ASX 200 Index (ASX: XJO) has shaken off the malaise that has been gripping it this week and posted a strong gain at this point of Wednesday’s trading session. At the time of writing, the ASX 200 has gained a very healthy 1.35%,...

ASX 200 gold shares are having a top run on the market today amid higher gold prices. Gold explorers in the green include Evolution Mining Ltd (ASX: EVN), Newcrest Mining Ltd (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) Let’s tak...

Investors were caught off guard yesterday after the Bank of Japan (BoJ) broke decades of monetary tradition. The central bank’s decision to widen the acceptable band on the country’s risk-free rate was met with blood in equity markets. In...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has bounced back from yesterday’s selloff. At the time of writing, the benchmark index is up 1.3% to 7,117.2 points. Four ASX shares that are climbing more than most today are lis...

21 Dec 2022 - A snapshot of the stocks on the move featuring Matrix Composites & Engineering (ASX:MCE), DroneShield (ASX:DRO) and MedAdvisor (ASX:MDR).

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] MedAdvisor (ASX: MDR) has revealed it expects revenue for the six months ending December 2022 (H1 FY2023) to be up 50-60% on H1 FY2022 levels due to the company’s US...

An acquisitive couple of years is starting to pay off for pharmacy tech company MedAdvisor (ASX: MDR) which has forecast a spike of between 50 and 60 per cent in first-half revenue for FY23. MedAdvisor is expecting revenue to land between...

Markets overnight were scrambling to adjust to a shock move by the Bank of Japan to allow the yield on 10-year Japanese government bonds to shift up to 0.50 per cent instead of its long-preferred 0.25 per cent cap. In a nutshell, Japan’s be...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ASX healthcare shares have been a mixed bag this earnings season, with some names completely blowing it out of the park, whereas others have left more to be desired. The S&P/ASX 200 Health Care index (ASX: XHJ) finished up 122 basis p...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Equitable In...

ASX 200 is flat Small Caps index is flatter, let’s call it tepid Lots of fun rumours to dissect   So the Hang Seng Tech index lost nearly 2% when it opened this morning. And while most major indices across the Asia-Pacific ‘hood were inde...

MedAdvisor (MDR) enters into a trading halt ahead of a $14.6 million capital raise to support accelerated growth and the planned acquisition of GuildLink The acquisition of GuildLink will enable MedAdvisor to provide a consolidated platfor...

Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am...

Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

MedAdvisor (MDR) appoints US-based CEO and Managing Director, Rick Ratliff In April, current CEO and MD Robert Read announced his intention to retire from the role as he wasn’t prepared to move to the US, in line with the company’s growth...

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....